Queue study for gestational trophoblastic neoplasia
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is creating a database for women diagnosed with gestational trophoblastic neoplasia (GTN), which includes tumors that can develop after a molar pregnancy or other pregnancy-related conditions. By joining, you help researchers better understand and improve treatment for these rare tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of gestational trophoblastic neoplasia (GTN), such as invasive mole, choriocarcinoma, or related types.
- You must be able to provide informed consent (understand and agree to participate).
- You must not have another active malignant (cancerous) tumor.
- You must not have a mental illness or cognitive impairment that would prevent you from completing the study.
- You must not have major missing follow-up data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a hysteroscope (a tiny camera) to gently scrape the uterus again, instead of starting chemotherapy right away, can effectively treat a low-risk, pregnancy-related tumor that returns after a molar pregnancy. It's for Chinese women whose disease is still in an early, low-risk stage.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (actinomycin-D) as the first treatment for gestational trophoblastic neoplasia (GTN) with a FIGO score of 5-6. It may help patients whose disease is at a moderate risk level.
This study looks at the emotional and psychological well-being of women after finishing chemotherapy for gestational trophoblastic neoplasia (GTN). It asks women about their feelings and experiences to better understand and support others going through similar treatment.
This study looks at giving pembrolizumab (a type of immune treatment) before a second evacuation procedure in people with persistent or returning molar pregnancy cancer. The goal is to see if this approach is safe and feasible, and whether it may help control the disease.
This trial tests a combination of two drugs — toripalimab (an immunotherapy) and actinomycin-D (chemotherapy) — as the first treatment for a specific type of pregnancy-related tumor (GTN) with a FIGO score of 7. The goal is to see if this combination works better than standard treatment.
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
Hear when a new Gestational Trophoblastic Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.